Genoss Co., Ltd.

Since its establishment in 2004, GENOSS made an endeavor to become the world’s leading medical device company. The primary mission set forth by GENOSS is focusing on delivering treatment solutions and promoting the well-being of its consumers and patients. GENOSS is trying to prepare for a bigger leap forward into the endless competition of the world biotechnology market through our technical innovation. GENOSS has demonstrated a strong commitment to Research & Development, spending considerable portion on R&D as a percentage of sales. GENOSS has immensely experienced and talented R&D professionals for manufacturing world-beating

quality of products. In addition, GENOSS strictly fulfills and complies with the international quality regulations, including KGMP, ISO 13485 and ISO 9001. Furthermore, the CE mark on each product confirms its conformity with all of the legal requirements.

GEONSS always concentrates on our customers and patients with the very high levels of innovation and technical expertise, providing a wide range of products categorized as vascular devices , Spinal devices , Dermal filler and Bone & Tissue. GENOSS is desired to build on values of trustworthiness and strong partnerships with customers and business partners.



MONALISA is a high purity hyaluronic acid filler which keeps the excellent volume effect for a long time at the beginning of the procedure, being decomposed naturally over time.
Depending on particle size, you can choose appropriate products from soft, mild to hard type.

1. Volume Effect and Retention
    The uniform sized hyaluronic acid particles with optimal viscoelasticity can maintain a long-lasting
    volume.

2. Safe to Use on Patients
     The ergonomically-designed rod and grip allow the even distribution of pressure during injection
     to enable an accurate and safe treatment for both the clinician and the patient.

3. Easy Procedural Operation
    GENOSS implements a strict quality control system through direct involvement in the entire production process
    from the base material of hyaluronic acid to the final product.

4. Highly Pure Hyaluronic Acid
     To guarantee the quality of MONALISA, GENOSS strictly fulfills and complies with the international
     quality regulations, including KGMP,ISO 13485 and ISO 9001.

5. Global Standard Quality Control
     MONALISA is safe to use on patients due to low level of endotoxin and essentially no BDDE residue.
     The uniform sized hyaluronic acid particles with optimal viscoelasticity can maintain a long-lasting
     volume.

∙ Designed for quick and easy in/deflation of balloon catheter
∙ 30atm pressure and 20cc volume
∙ Ergonomic, highly reliable, accurate, stable and quick release
 

∙ Smooth introductioin and easy removal of medical devices
∙ Dual valve technology minimizing fluid loss
∙ Optimized an

∙ Sonic wave electric toothbrush
∙ Replacement brush heads by type
∙ Waterproof under daily circumstances

∙3d Cage is produced with Selective Laser Melting[SLM] technique
∙ Bone grafting is not necessary
   (Consists of ~88% porosity and pore size of 250㎛~1,200㎛ )
∙ Suitable elastic modulus avoids stress shielding and bone resorption

· 70µm of Co-Cr strut thickness
· Bioresorbable polymer abluminal coating (thickness < 4µm)
· Sirolimus dose 1.15µm / mm²